肠道菌群与肠道疾病的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.22.003

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (22): 3162-3165.DOI: 10.3760/cma.j.issn.1007-1245.2023.22.003

肠道菌群与肠道疾病的研究进展

付新年¹ 郑盛² 杨涓²

¹大理大学，大理　671003；²大理大学第二附属医院云南省第三人民医院消化内科，昆明　650011

收稿日期:2023-06-25 出版日期:2023-11-15 发布日期:2023-11-23
通讯作者: 杨涓，Email：53573885@qq.com
基金资助:
云南省科技厅科技计划项目（2018FH001-076、2018FH001-080）；云南省教育厅科学研究基金立项项目（2023J0926）；大理大学第八期教育教学改革研究项目（2022JGYX08-01、2022JGYX08-02）

Research progress of intestinal flora and intestinal diseases

Fu Xinnian¹, Zheng Sheng², Yang Juan²

¹Dali University, Dali 671003, China; ²Department of Gastroenterology, Yunnan Third People's Hospital, Second Hospital, Dali University, Kunming 650011, China

Received:2023-06-25 Online:2023-11-15 Published:2023-11-23
Contact: Yang Juan, Email: 53573885@qq.com
Supported by:
Project of Scientific and Technological Plan of Yunnan Department of Science and Technology (2018FH001-076 and 2018FH001-080); Project Supported by Scientific Research Fund of Yunnan Education Department (2023J0926); Research Project of Eighth Education and Teaching Reform of Dali University (2022JGYX08-01 and 2022JGYX08-02)

摘要/Abstract

摘要：

肠道菌群与肠道疾病的发生发展有着紧密的联系，它在维持肠道稳态方面起着重要作用。本文对肠道菌群与肠道疾病［结直肠息肉、结直肠癌（CRC）、炎症性肠病（IBD）、肠易激综合征（IBS）］的研究进展展开综述，旨在为肠道疾病的预防、诊断及治疗提供参考。

关键词:

肠道菌群, 结肠息肉, 结直肠癌, 炎症性肠病, 肠易激综合征, 进展

Abstract:

Intestinal flora is closely related to the occurrence and development of intestinal diseases and plays an important role in maintaining intestinal homeostasis. In this paper, the research progress of intestinal flora and intestinal diseases, including colorectal polyps, colorectal cancer, inflammatory bowel disease, and irritable bowel syndrome, is reviewed, so as to provide references for the prevention, diagnosis, and treatment of intestinal diseases.

Key words:

Intestinal flora, Colon polyp, Colorectal cancer, Inflammatory bowel disease, Irritable bowel syndrome, Progress

付新年郑盛杨涓.

肠道菌群与肠道疾病的研究进展 [J]. 国际医药卫生导报, 2023, 29(22): 3162-3165.

Fu Xinnian, Zheng Sheng, Yang Juan.

Research progress of intestinal flora and intestinal diseases [J]. International Medicine and Health Guidance News, 2023, 29(22): 3162-3165.

参考文献

[1] Guo X, Okpara ES, Hu W,et al. Interactive relationships between intestinal flora and bile acids[J]. Int J Mol Sci,2022,23(15):8343.DOI: 10.3390/ijms23158343.
[2] Fu Q, Song T, Ma X,et al. Research progress on the relationship between intestinal microecology and intestinal bowel disease[J]. Animal Model Exp Med,2022,5(4):297-310.DOI: 10.1002/ame2.12262.
[3] Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in Human Disease[J]. Front Cell Infect Microbiol,2021,11:625913.DOI: 10.3389/fcimb.2021.625913.
[4] Ma PJ, Wang MM, Wang Y. Gut microbiota: a new insight into lung diseases[J]. Biomed Pharmacother,2022,155:113810.DOI: 10.1016/j.biopha.2022.113810.
[5] Meng X, Zhang G, Cao H,et al. Gut dysbacteriosis and intestinal disease: mechanism and treatment[J]. J Appl Microbiol,2020,129(4):787-805.DOI: 10.1111/jam.14661.
[6] Sullivan BA, Noujaim M, Roper J. Cause, epidemiology, and histology of polyps and pathways to colorectal cancer[J]. Gastrointest Endosc Clin N Am,2022,32(2):177-194.DOI: 10.1016/j.giec.2021.12.001.
[7] Zhong X, Wang Y, Xu J,et al. Gut microbiota signatures in tissues of the colorectal polyp and normal colorectal mucosa, and faeces[J]. Front Cell Infect Microbiol,2023,12:1054808.DOI: 10.3389/fcimb.2022.1054808.
[8] 徐俊,陈冰心,朱永亮,等. 结直肠腺瘤的肠道微生态分析及临床意义[J]. 中国医药导报,2022,19(16):30-33.
[9] Liang S, Mao Y, Liao M,et al. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps[J]. Int J Biol Sci,2020,16(1):135-146.DOI: 10.7150/ijbs.37399.
[10] Hale VL, Chen J, Johnson S,et al. Shifts in the fecal microbiota associated with adenomatous polyps[J]. Cancer Epidemiol Biomarkers Prev,2017,26(1):85-94.DOI: 10.1158/1055-9965.EPI-16-0337.
[11] Liang JQ, Li T, Nakatsu G,et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer[J]. Gut,2020,69(7):1248-1257.DOI: 10.1136/gutjnl-2019-318532.
[12] Pop OL, Vodnar DC, Diaconeasa Z,et al. An overview of gut microbiota and colon diseases with a focus on adenomatous colon polyps[J]. Int J Mol Sci,2020,21(19):7359.DOI: 10.3390/ijms21197359.
[13] Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer[J]. Front Immunol,2020,11:615056.DOI: 10.3389/fimmu.2020.615056.
[14] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A,et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli[J]. Nature,2020,580(7802):269-273.DOI: 10.1038/s41586-020-2080-8.
[15] Yu LC, Wei SC, Li YH,et al. Invasive pathobionts contribute to colon cancer initiation by counterbalancing epithelial antimicrobial responses[J]. Cell Mol Gastroenterol Hepatol,2022,13(1):57-79.DOI: 10.1016/j.jcmgh.2021.08.007.
[16] Wu Y, Jiao N, Zhu R,et al. Identification of microbial markers across populations in early detection of colorectal cancer[J]. Nat Commun,2021 ,12(1):3063.DOI: 10.1038/s41467-021-23265-y.
[17] Reis SAD, da Conceição LL, Peluzio MDCG. Intestinal microbiota and colorectal cancer: changes in the intestinal microenvironment and their relation to the disease[J]. J Med Microbiol,2019,68(10):1391-1407.DOI: 10.1099/jmm.0.001049.
[18] Yinhang W, Wei W, Jing Z,et al. Biological roles of toll-like receptors and gut microbiota in colorectal cancer[J]. Future Microbiol,2022,17:1071-1089.DOI: 10.2217/fmb-2021-0072.
[19] Rezasoltani S, Ghanbari R, Looha MA,et al. Expression of main toll-like receptors in patients with different types of colorectal polyps and their relationship with gut microbiota[J]. Int J Mol Sci,2020,21(23):8968.DOI: 10.3390/ijms21238968.
[20] Gao C, Qiao T, Zhang B,et al. TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression[J]. Onco Targets Ther,2018,11:5963-5971.DOI: 10.2147/OTT.S174274.
[21] Sheng Q, Du H, Cheng X,et al. Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites[J]. Oncol Lett,2019,18(5):4834-4844.DOI: 10.3892/ol.2019.10841.
[22] Feng J, Gong Z, Sun Z,et al. Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer[J]. Front Microbiol,2023,14:1034325.DOI: 10.3389/fmicb.2023.1034325.
[23] Chen F, Dai X, Zhou CC,et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma[J]. Gut,2022,71(7):1315-1325. DOI: 10.1136/gutjnl-2020-323476.
[24] Miyoshi J, Chang EB. The gut microbiota and inflammatory bowel diseases[J]. Transl Res,2017,179:38-48.DOI: 10.1016/j.trsl.2016.06.002.
[25] Hu Y, Chen Z, Xu C,et al. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel Disease[J]. Nutrients,2022,14(23):5140.DOI: 10.3390/nu14235140.
[26] Inczefi O, Bacsur P, Resál T,et al. The influence of nutrition on intestinal permeability and the microbiome in health and disease[J]. Front Nutr,2022,9:718710.DOI: 10.3389/fnut.2022.718710.
[27] Caruso R, Lo BC, Núñez G. Host-microbiota interactions in inflammatory bowel disease[J]. Nat Rev Immunol,2020,20(7):411-426.DOI: 10.1038/s41577-019-0268-7.
[28] Colman RJ, Tsai YT, Jackson K,et al. Achieving target infliximab drug concentrations improves blood and fecal neutrophil biomarkers in crohn's disease[J]. Inflamm Bowel Dis,2021,27(7):1045-1051.DOI: 10.1093/ibd/izaa241.
[29] Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review[J]. Antonie Van Leeuwenhoek,2020,113(12):2019-2040.DOI: 10.1007/s10482-020- 01474-7.
[30] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol,2020,17(4):223-237.DOI: 10.1038/s41575-019-0258-z.
[31] Sasaki K, Inoue J, Sasaki D,et al. Construction of a model culture system of human colonic microbiota to detect decreased lachnospiraceae abundance and butyrogenesis in the feces of ulcerative colitis patients[J]. Biotechnol J,2019,14(5):e1800555.DOI: 10.1002/biot.201800555.
[32] Chen M, Feng Y, Liu W. Efficacy and safety of probiotics in the induction and maintenance of inflammatory bowel disease remission: a systematic review and meta-analysis[J]. Ann Palliat Med,2021,10(11):11821-11829.DOI: 10.21037/apm-21-2996.
[33] Leonardi I, Paramsothy S, Doron I,et al. Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis[J]. Cell Host Microbe,2020,27(5):823-829.e3.DOI: 10.1016/j.chom.2020.03.006.
[34] Kim GH, Lee K, Shim JO. Gut bacterial dysbiosis in irritable bowel syndrome: a case-control study and a cross-cohort analysis using publicly available data sets[J]. Microbiol Spectr,2023,11(1):e0212522.DOI: 10.1128/spectrum.02125-22.
[35] Mamieva Z, Poluektova E, Svistushkin V,et al. Antibiotics, gut microbiota, and irritable bowel syndrome: what are the relations?[J]. World J Gastroenterol,2022,28(12):1204-1219.DOI: 10.3748/wjg.v28.i12.1204.
[36] Ji M, Huang H, Lan X. Correlation between intestinal microflora in irritable bowel syndrome and severity[J]. Dis Markers,2022,2022:1031844.DOI: 10.1155/2022/1031844.
[37] Frost F, Kacprowski T, Rühlemann MC,et al. Functional abdominal pain and discomfort (IBS) is not associated with faecal microbiota composition in the general population[J]. Gut,2019,68(6):1131-1133.DOI: 10.1136/gutjnl-2018-316502.
[38] Maharshak N, Ringel Y, Katibian D,et al. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome[J]. Dig Dis Sci,2018,63(7):1890-1899.DOI: 10.1007/s10620-018-5086-4.
[39] Asha MZ, Khalil SFH. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis[J]. Sultan Qaboos Univ Med J,2020,20(1):e13-e24.DOI: 10.18295/squmj.2020.20.01.003.
[40] El-Salhy M, Hatlebakk JG, Gilja OH,et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study[J]. Gut,2020,69(5):859-867.DOI: 10.1136/gutjnl-2019-319630.
[41] Sun JR, Kong CF, Qu XK,et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis[J]. Saudi J Gastroenterol,2020,26(2):66-77.DOI: 10.4103/sjg.SJG_384_19.

肠道菌群与肠道疾病的研究进展

Research progress of intestinal flora and intestinal diseases

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[2]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[3]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[4]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[5]	耿松卢清军任翔蒋宏. MicroRNAs在结直肠炎癌转化过程中的作用 [J]. 国际医药卫生导报, 2023, 29(7): 903-909.
[6]	王凤燕王胜果于呈祥韩志浩. 标准化碘密度诊断结直肠癌淋巴结转移的价值 [J]. 国际医药卫生导报, 2023, 29(7): 923-928.
[7]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[8]	耿泽月张兴凯杜刚强周楠赵冬阳王志刚. 髓内钉治疗股骨中下段骨折的并发症分析 [J]. 国际医药卫生导报, 2023, 29(23): 3321-3324.
[9]	张辰喜王鹏飞潘欣刘紫仪张勇. 艾司氯胺酮在临床麻醉中的应用进展 [J]. 国际医药卫生导报, 2023, 29(23): 3325-3329.
[10]	肖曦　石斗飞. 维生素C在呼吸道感染中应用的研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3330-3335.
[11]	司航王娜娜刘素素张骞. PP1A在肿瘤发生发展过程中的作用及研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3336-3340.
[12]	付志鹏郑盛杨涓. 肝硬化患者营养评价方法研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3341-3344.
[13]	刘丽英魏丽娟张妙贤唐盈玉张超米. 炎症性肠病患儿父母疾病认知调查分析 [J]. 国际医药卫生导报, 2023, 29(23): 3497-3500.
[14]	蔡金凤王洪财葛汝丽. 肠道菌群失衡在帕金森病α-突触核蛋白诱导小胶质细胞活化中的作用 [J]. 国际医药卫生导报, 2023, 29(22): 3153-3157.
[15]	谢爱霞李强强何炎鸿化得武陈丽萍薛建军. B超引导下注射富血小板血浆联合神经阻滞治疗肩周炎的研究进展 [J]. 国际医药卫生导报, 2023, 29(22): 3157-3161.